Livzon Pharma Unit's Plaque Psoriasis Drug Granted Priority Review in China

MT Newswires Live

01/07

Livzon Pharmaceutical Group (HKG:1513, SHE:000513) said the Lecankitug Injection was included in the public list of drugs proposed for priority review by China's National Medical Products Administration, according to a Wednesday Hong Kong bourse filing.

The drug, jointly developed by Livzon MABPharm, a controlling subsidiary of the company, and Beijing Xinkanghe Biopharmaceutical Technology, has now entered the priority review and approval process for marketing authorization.

The drug is indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2601803050"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2601803050\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2601803050?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-07 21:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601803050","market":"fut","top_or_hot":-1,"title":"Livzon Pharma Unit's Plaque Psoriasis Drug Granted Priority Review in China","media":"MT Newswires Live","content":"<html><body><p> Livzon Pharmaceutical Group (HKG:1513, SHE:000513) said the Lecankitug Injection was included in the public list of drugs proposed for priority review by China's National Medical Products Administration, according to a Wednesday Hong Kong bourse filing.</p><p>The drug, jointly developed by Livzon MABPharm, a controlling subsidiary of the company, and Beijing Xinkanghe Biopharmaceutical Technology, has now entered the priority review and approval process for marketing authorization.</p><p>The drug is indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Livzon Pharma Unit's Plaque Psoriasis Drug Granted Priority Review in China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLivzon Pharma Unit's Plaque Psoriasis Drug Granted Priority Review in China\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-01-07 21:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Livzon Pharmaceutical Group (HKG:1513, SHE:000513) said the Lecankitug Injection was included in the public list of drugs proposed for priority review by China's National Medical Products Administration, according to a Wednesday Hong Kong bourse filing.</p><p>The drug, jointly developed by Livzon MABPharm, a controlling subsidiary of the company, and Beijing Xinkanghe Biopharmaceutical Technology, has now entered the priority review and approval process for marketing authorization.</p><p>The drug is indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0028","symbol_name":"国家队","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2601803050","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601803050","pubTimestamp":1767791551,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Livzon Pharmaceutical Group  said the Lecankitug Injection was included in the public list of drugs proposed for priority review by China's National Medical Products Administration, according to a Wednesday Hong Kong bourse filing.The drug, jointly developed by Livzon MABPharm, a controlling subsidiary of the company, and Beijing Xinkanghe Biopharmaceutical Technology, has now entered the priority review and approval process for marketing authorization.The drug is indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK0028":"国家队","BK0239":"医药制造","01513":"丽珠医药","000513":"丽珠集团","BK1191":"制药","BK0188":"融资融券","BK0187":"一线龙头"},"translate_title":"丽珠医药旗下斑块型银屑病药物获中国优先审评","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"000513":0.9,"01513":0.9},"content_text":"Livzon Pharmaceutical Group (HKG:1513, SHE:000513) said the Lecankitug Injection was included in the public list of drugs proposed for priority review by China's National Medical Products Administration, according to a Wednesday Hong Kong bourse filing.The drug, jointly developed by Livzon MABPharm, a controlling subsidiary of the company, and Beijing Xinkanghe Biopharmaceutical Technology, has now entered the priority review and approval process for marketing authorization.The drug is indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}